Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Benign Hematology and
1 other channel

Journal Scan / Research · January 19, 2022

Anticoagulantion for 6 Weeks vs 3 Months in Patients <21 Years With Provoked VTE

JAMA: The Journal of the American Medical Association

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Sanjay Ahuja MD, MSc, MBA

JAMA: The Journal of the American Medical Association
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial
JAMA 2022 Jan 11;327(2)129-137, NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca, JF Casella, RA Dale, JL Halperin, F Hamblin, CM Kessler, MJ Manco-Johnson, RF Sidonio, AC Spyropoulos, PG Steg, AGG Turpie, S Schulman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated